U.S. Department of Health & Human Services      Search the NIH Website
          Virtual Tour
          Staff Directory
          En Español Site Menu Home
			
			Health Information
				Health Care Providers & Facilities
							Health Info Lines
							HealthCare.gov
							Science Education Resources
							NIH Clinical Research Trials and You
							Talking to Your DoctorMore »
					Search Health Topics
						Quick Links
						MedlinePlus Health Info
							NIH News in Health
							Wellness Toolkits
			
			Grants & Funding
				Grants Home Page
							Find Funding
							Due Dates
							How to Apply
							About Grants
							Policy & Compliance
							Grants News/Blog
							Contracts
							Loan RepaymentMore »
					Quick Links
						RePORT
							eRA Commons
							NIH Common Fund
			
			News & Events
				News Releases
							Digital Media Kits
							Media Resources
							Media Contacts
							Images and B-roll
							Events
							Social MediaMore »
					Quick Links
						NIH News in Health
							NIH Research Matters
							NIH Record
			
			Research & Training
				Medical Research Initiatives
							Science Highlights
							Science Education
							Research in NIH Labs & Clinics
							Training Opportunities
							Library Resources
							Research Resources
							Clinical Research Resources
							Safety, Regulation and GuidanceMore »
					Quick Links
						PubMed
							Stem Cell Information
							OppNet
							NIDB
							NIH Blueprint for Neuroscience Research
			
			Institutes at NIH
				List of Institutes and Centers
							NIH Office of the Director
							Directors of NIH Institutes and Centers
							NIH Institute and Center Contact InformationMore »
					Quick Links
						NCI
              	NEI
              	NHLBI
              	NHGRI
              	NIA
              	NIAAA
              	NIAID
              	NIAMS
              	NIBIB
              	NICHD
              	NIDCD
              	NIDCR
              	NIDDK
              	NIDA
              	NIEHS
              	NIGMS
              	NIMH
              	NIMHD
              	NINDS
              	NINR
              	NLM
              	CC
              	CIT
              	CSR
              	FIC
              	NCATS
              	NCCIH
			
			About NIH
				Who We Are
							What We Do
							Jobs at NIH
							Visitor Information
							Frequently Asked Questions
							Contact UsMore »
					Quick Links
						The NIH Director
							Take the Virtual Tour
							NIH...Turning Discovery Into Health®
							Impact of NIH Research
							Science, Health, and Public Trust
 You are here Home News & Events News Releases
 News Releases
 Media Advisory Wednesday, April 3, 2024 Drug shows promise for slowing progression of rare, painful genetic disease NIH-supported clinical trial could lead to first effective treatment for ACDC disease. A CT angiography scan of a person with ACDC disease showing abnormal calcification of the blood vessels in the legs and feet.
 What A drug used to treat certain bone diseases shows promise for slowing the progression of a rare, painful genetic condition that causes excessive calcium buildup in the arteries, known as arterial calcification due to deficiency of CD73 (ACDC). These results are from a first-in-human clinical trial supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. The study, published in the journal *Vascular Medicine*, could lead to the first effective treatment for the rare disease. ACDC, which has no known cure, often targets the arteries of the legs and can make walking painful and difficult. It can also affect the joints of the hands, causing pain and deformities. In severe cases, the condition can lead to potential limb loss. Symptoms of the disease often begin in the late teens and 20s. An extremely rare disease, it is believed to affect only about 20 people worldwide and has an estimated prevalence of less than 1 in 1 million. Previous studies have identified the gene for ACDC disease and the biochemical mechanism behind it. More recent studies by the NHLBI research team identified an existing drug, called etidronate, as a potential treatment for ACDC based on disease models in animals and human cells. In the study, researchers evaluated the safety and effectiveness of etidronate in treating calcification of the arteries and impaired blood flow in the legs of seven people (four women and three men) with ACDC disease. Although few, they collectively represent about one-third of all the known cases in the world. Treatment consisted of taking the oral drug daily for 14 days every three months over a three-year period. The researchers measured calcium deposits using CT scans and tested blood flow using the ankle brachial index, a non-invasive tool, both at the start of the study and as a yearly follow-up after treatment.
	Researchers found that etidronate treatments appeared safe, with no adverse side effects reported. The drug appeared to slow the progression of new calcium deposits in the blood vessels of the legs as well as slow the progression of blood flow inhibition. However, the drug did not reverse calcium deposits that were already present in the affected blood vessels and joints, nor did it show clear improvement in blood flow. Questionnaires administered to the patients suggested that symptoms, such as pain and motion impairment, were improved. Researchers suggest that lessons learned from the current study could allow development of novel therapies for ACDC and larger clinical trials for this disease. The study could also shed light on other diseases involving excessive calcium buildup in the arteries, including peripheral artery disease and atherosclerosis. Reference Ferrante EA, Cudrici CD, Rashidi M, et al. Pilot study to evaluate the safety and effectiveness of etidronate treatment for arterial calcification due to deficiency of CD73 (ACDC). Vascular Medicine. 2024. doi: 10.1177/1358863X241235669 Who Elisa Ferrante, Ph.D., clinical program manager and staff scientist in the Translational Vascular Medicine Branch at NHLBI, and Alessandra Brofferio, M.D., clinical cardiologist with the Laboratory of Cardiovascular Regenerative Medicine of NHLBI. **About the National Heart, Lung, and Blood Institute (NHLBI):** NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. For more information, visit www.nhlbi.nih.gov. **About the National Institutes of Health (NIH):**
NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. *NIH...Turning Discovery Into Health®* ###
 Institute/CenterNational Heart, Lung, and Blood Institute (NHLBI)ContactNHLBI Engagement and Media Relations Branch

  301-496-5449
Connect with Us
  
  Subscribe to news releases
	RSS Feed
 Connect with Us Contact Us
      X
      Facebook
      Instagram
      YouTube
      Flickr
      More Social Media from NIH
 Footer
    NIH Home
      Virtual Tour
      En Español
      Visitor Information
      Frequently Asked Questions
      Privacy Policy
      Disclaimers
      Accessibility
      NIH Website ArchivesNondiscrimination Notice
      Freedom of Information Act
      No Fear Act
      HHS Vulnerability Disclosure
      Office of Inspector General
      USA.govNIH...Turning Discovery Into Health®
    National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892
    U.S. Department of Health and Human Services
 Back to Top